Compare
Alnylam Pharmaceuticals, Inc. vs Perrigo Co PLC vs BioMarin Pharmaceutical Inc vs United Therapeutics Corp
| Latest fiscal year | Alnylam Pharmaceuticals, Inc. ALNY | Perrigo Co PLC PRGO | BioMarin Pharmaceutical Inc BMRN | United Therapeutics Corp UTHR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.71B | $4.25B | $3.22B | $3.18B |
| Revenue growth (YoY) | +65.2% | -2.8% | +12.9% | +10.6% |
| Gross margin | 81.8% (computed) | 35.1% | 77.7% (computed) | 87.9% (computed) |
| Operating margin | 13.5% | -26.4% | 12.7% | 46.9% |
| Net margin | 8.4% | -33.5% | 10.8% | 41.9% |
| Net income | $313.75M | -$1.43B | $348.90M | $1.33B |
| EPS (Diluted) | $2.33 | -$10.29 | $1.80 | $27.86 |
| Operating cash flow | $524.08M | $238.50M | $827.99M | $1.56B |
| Free cash flow | $465.38M | $145.10M | $724.96M | $1.04B |
| Cash & equivalents | $1.66B | n/a | $1.31B | $1.56B |
| Total assets | $4.97B | $8.54B | $7.59B | $7.88B |
| Total liabilities | $4.18B | $5.60B | $1.51B | $783.80M |
| Shareholders' equity | $789.18M | $2.94B | $6.09B | $7.10B |
| Return on year-end equity | 39.8% | -48.6% | 5.7% | 18.8% |
| Shares outstanding | 132.38M | 137.60M | 192.30M | 43.64M |
Revenue, most recent five fiscal years
| Fiscal year | Alnylam Pharmaceuticals, Inc. | Perrigo Co PLC | BioMarin Pharmaceutical Inc | United Therapeutics Corp |
|---|---|---|---|---|
| Latest | $3.71B Ended 2025-12-31 | $4.25B Ended 2025-12-31 | $3.22B Ended 2025-12-31 | $3.18B Ended 2025-12-31 |
| 1 year earlier | $2.25B Ended 2024-12-31 | $4.37B Ended 2024-12-31 | $2.85B Ended 2024-12-31 | $2.88B Ended 2024-12-31 |
| 2 years earlier | $1.83B Ended 2023-12-31 | $4.66B Ended 2023-12-31 | $2.42B Ended 2023-12-31 | $2.33B Ended 2023-12-31 |
| 3 years earlier | $1.04B Ended 2022-12-31 | $4.45B Ended 2022-12-31 | $2.10B Ended 2022-12-31 | $1.94B Ended 2022-12-31 |
| 4 years earlier | $844.29M Ended 2021-12-31 | $4.14B Ended 2021-12-31 | $1.85B Ended 2021-12-31 | $1.69B Ended 2021-12-31 |